BYSI vs. ENGN, FHTX, YMAB, NVCT, KRRO, INMB, TVGN, VYGR, ELDN, and INBX
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include enGene (ENGN), Foghorn Therapeutics (FHTX), Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), Korro Bio (KRRO), INmune Bio (INMB), Tevogen Bio (TVGN), Voyager Therapeutics (VYGR), Eledon Pharmaceuticals (ELDN), and Inhibrx (INBX). These companies are all part of the "pharmaceutical products" industry.
BeyondSpring vs.
enGene (NASDAQ:ENGN) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.
enGene presently has a consensus price target of $25.22, suggesting a potential upside of 468.07%. Given enGene's stronger consensus rating and higher probable upside, equities research analysts clearly believe enGene is more favorable than BeyondSpring.
enGene has a beta of -0.61, suggesting that its share price is 161% less volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
BeyondSpring's return on equity of 0.00% beat enGene's return on equity.
In the previous week, enGene had 3 more articles in the media than BeyondSpring. MarketBeat recorded 8 mentions for enGene and 5 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.00 beat enGene's score of -0.30 indicating that BeyondSpring is being referred to more favorably in the news media.
BeyondSpring has higher revenue and earnings than enGene.
64.2% of enGene shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
BeyondSpring received 166 more outperform votes than enGene when rated by MarketBeat users. However, 95.00% of users gave enGene an outperform vote while only 66.79% of users gave BeyondSpring an outperform vote.
Summary
BeyondSpring beats enGene on 8 of the 15 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
This page (NASDAQ:BYSI) was last updated on 4/3/2025 by MarketBeat.com Staff
